Detailed Information on Publication Record
2018
Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission
VYDRA, Jan, Cyril ŠÁLEK, Jiří SCHWARZ, Pavel ŽÁK, Jan NOVÁK et. al.Basic information
Original name
Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission
Authors
VYDRA, Jan (203 Czech Republic, guarantor, belonging to the institution), Cyril ŠÁLEK (203 Czech Republic), Jiří SCHWARZ (203 Czech Republic), Pavel ŽÁK (203 Czech Republic), Jan NOVÁK (203 Czech Republic), Veronika PETEČUKOVÁ (203 Czech Republic), Pavla PECHERKOVÁ (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution), Petr CETKOVSKÝ (203 Czech Republic) and Zdeněk RÁČIL (203 Czech Republic, belonging to the institution)
Edition
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, DALLAS, CIG MEDIA GROUP, LP, 2018, 2152-2650
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.274
RIV identification code
RIV/00216224:14110/18:00106923
Organization unit
Faculty of Medicine
UT WoS
000425919600009
Keywords in English
Acute myeloid leukemia; Chemotherapy; Hematopoietic stem cell transplantation
Tags
International impact, Reviewed
Změněno: 9/2/2019 20:26, Soňa Böhmová
Abstract
V originále
Curative treatment of acute myeloid leukemia (AML) is based on one or two cycles of remission induction chemotherapy followed by consolidation chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in those patients who enter complete remission (CR). We present analysis of course and outcome of postremission therapy in 310 patients with AML with intermediate risk cytogenetics. Background: We retrospectively analyzed data from 310 patients with acute myeloid leukemia with intermediate-risk cytogenetics in first complete remission (CR1) to evaluate the usage and efficacy of various types of postremission therapy. Patients and Methods: Cox regression with time-dependent covariates, landmark analysis, and competing risk models were used to estimate the outcomes and effects of treatment and patient- and disease-related risk factors. Results: The early relapse rate and early nonrelapse mortality (NRM) were 12.8% and 4.4%, respectively. In our study, 77.2% of patients completed postremission therapy: 44% received allogeneic hematopoietic cell transplantation (HCT), 20% completed treatment with high-dose cytarabine (HIDAC), and 13% completed treatment with intermediate- dose cytarabine. The 3-year overall survival rate was 67.5% for patients treated with HIDAC and 63.4% after HCT (P =.5876). The NRM and relapse rate at 3 years were 0% and 58.9% after HIDAC and 21.9% and 29.3% after HCT, respectively. HCT reduced the risk of relapse (hazard ratio, 0.6; 95% confidence interval, 0.36-0.98). Total body irradiation-based myeloablative conditioning increased NRM compared with busulfan-based conditioning (hazard ratio, 8.33; 95% confidence interval, 2.52-27.45). Conclusion: Most patients with acute myeloid leukemia with intermediate- risk cytogenetics received allogeneic HCT, which decreased the risk of relapse but increased NRM, leading to a similar overall survival for patients who received HCT and HIDAC. Our data support the use of allogeneic transplantation for patients in CR1 from a human leukocyte antigen-matched related or unrelated donor after a busulfan-based myeloablative conditioning regimen as a primary strategy of postremission therapy for eligible younger patients.
Links
| NV15-25809A, research and development project |
|